Example. popPK-Data-Standard-Example-combined example with and IV dose

This example shows a combined dataset from multiple studies: the examples from Sections 6, Example: One Subject, Single Dose, and 7, Example: One Subject, Multiple Doses, are combined with the addition of an IV dose. This combined example includes both a tablet and IV.

$titleHtml

	PROJID	PROJIDN	STUDYID	STUDYIDN	PART	USUBJID	USUBJIDN	SUBJID	SITEID	SITEIDN	AVISIT	AVISITN	VISIT	VISITNUM	AFRLT	TPTREF	APRLT	NFRLT	NPRLT	ATPT	ATPTN	ADT	ATM	ADY	AENDT	AENTM	OCC	DVID	DVIDN	CMT	DV	DVL	EVID	MDV	AULOQ	ALLOQ	BLQFN	BLQFL	ALQFN	ALQFL	DOSEA	DOSEP	AMT	II	ADDL	RATE	DUR	FORM	FORMN	ROUTE	ROUTEN	TRTP	TRTPN	TRTA	TRTAN	APHASE	APHASEN	APERIOD	APERIODC	ARM	ARMN	ACTARM	ACTARMN	COHORT	COHORTN	WT	WTBL	HTBL	BMIBL	BSABL	AGE	SEX	SEXN	RACE	RACEN	ETHNIC	ETHNICN	REGION	REGIONN	COUNTRY	COUNTRYN	CREATBL	UCREATBL	CRCLBL	EGFRBL	TBILBL	ASTBL	ALTBL	AVAL	PCSTRESC
1	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	-0.1	DAY 1 DOSE	-0.1	0	0	PREDOSE	0	2020-05-21	07:54	1			1	DRUG (ng/mL)	1	2	.	.	0	1	10000	1	1	Y	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	.	BLQ
2	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	-0.1	DAY 1 DOSE	-0.1	0	0	PREDOSE	0	2020-05-21	07:54	1			1	BIOMARKER (ng/mL)	2	5	87.03	4.466299	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	87.03	87.03
3	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	0	DAY 1 DOSE	0	0	0	DOSE	0	2020-05-21	08:00	1			1	TEST PRODUCT (mg)	0	1	.	.	1	1	10000	1	0	N	0	N	100	100	100	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	.
4	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	0.25	DAY 1 DOSE	0.25	0.25	0.25	15MIN	0.25	2020-05-21	08:15	1			1	DRUG (ng/mL)	1	2	1.97	0.678629	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	1.97	1.97
5	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	0.25	DAY 1 DOSE	0.25	0.25	0.25	15MIN	0.25	2020-05-21	08:15	1			1	BIOMARKER (ng/mL)	2	5	70.02	4.248754	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	70.02	70.02
6	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	0.5	DAY 1 DOSE	0.5	0.5	0.5	30MIN	0.5	2020-05-21	08:30	1			1	DRUG (ng/mL)	1	2	2.98	1.090316	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	2.98	2.98
7	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	0.5	DAY 1 DOSE	0.5	0.5	0.5	30MIN	0.5	2020-05-21	08:30	1			1	BIOMARKER (ng/mL)	2	5	73.69	4.299825	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	73.69	73.69
8	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	0.75	DAY 1 DOSE	0.75	0.75	0.75	45MIN	0.75	2020-05-21	08:45	1			1	DRUG (ng/mL)	1	2	6.44	1.861801	0	1	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	6.44	6.44
9	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	0.75	DAY 1 DOSE	0.75	0.75	0.75	45MIN	0.75	2020-05-21	08:45	1			1	BIOMARKER (ng/mL)	2	5	76.98	4.343546	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	76.98	76.98
10	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	1	DAY 1 DOSE	1	1	1	1H	1	2020-05-21	09:00	1			1	DRUG (ng/mL)	1	2	9.80	2.282835	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	9.80	9.8
11	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	1	DAY 1 DOSE	1	1	1	1H	1	2020-05-21	09:00	1			1	BIOMARKER (ng/mL)	2	5	65.98	4.189386	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	65.98	65.98
12	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	1.5	DAY 1 DOSE	1.5	1.5	1.5	1H30MIN	1.5	2020-05-21	09:30	1			1	DRUG (ng/mL)	1	2	12.41	2.518406	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	12.41	12.41
13	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	1.5	DAY 1 DOSE	1.5	1.5	1.5	1H30MIN	1.5	2020-05-21	09:30	1			1	BIOMARKER (ng/mL)	2	5	71.67	4.272099	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	71.67	71.67
14	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	2	DAY 1 DOSE	2	2	2	2H	2	2020-05-21	10:00	1			1	DRUG (ng/mL)	1	2	9.21	2.219783	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	9.21	9.21
15	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	2	DAY 1 DOSE	2	2	2	2H	2	2020-05-21	10:00	1			1	BIOMARKER (ng/mL)	2	5	81.56	4.401337	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	81.56	81.56
16	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	3	DAY 1 DOSE	3	3	3	3H	3	2020-05-21	11:00	1			1	DRUG (ng/mL)	1	2	17.40	2.856257	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	17.40	17.4
17	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	3	DAY 1 DOSE	3	3	3	3H	3	2020-05-21	11:00	1			1	BIOMARKER (ng/mL)	2	5	71.20	4.265473	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	71.20	71.2
18	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	4	DAY 1 DOSE	4	4	4	4H	4	2020-05-21	12:00	1			1	DRUG (ng/mL)	1	2	14.24	2.655828	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	14.24	14.24
19	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	4	DAY 1 DOSE	4	4	4	4H	4	2020-05-21	12:00	1			1	BIOMARKER (ng/mL)	2	5	60.43	4.101539	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	60.43	60.43
20	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	6	DAY 1 DOSE	6	6	6	6H	6	2020-05-21	14:00	1			1	DRUG (ng/mL)	1	2	16.98	2.831832	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	16.98	16.98
21	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	6	DAY 1 DOSE	6	6	6	6H	6	2020-05-21	14:00	1			1	BIOMARKER (ng/mL)	2	5	84.68	4.438878	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	84.68	84.68
22	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	8	DAY 1 DOSE	8	8	8	8H	8	2020-05-21	16:00	1			1	DRUG (ng/mL)	1	2	12.99	2.564352	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	12.99	12.99
23	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	8	DAY 1 DOSE	8	8	8	8H	8	2020-05-21	16:00	1			1	BIOMARKER (ng/mL)	2	5	86.48	4.459932	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	86.48	86.48
24	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	12	DAY 1 DOSE	12	12	12	12H	12	2020-05-21	20:00	1			1	DRUG (ng/mL)	1	2	19.51	2.970776	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	19.51	19.51
25	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 1	1	DAY 1	1	12	DAY 1 DOSE	12	12	12	12H	12	2020-05-21	20:00	1			1	BIOMARKER (ng/mL)	2	5	75.16	4.319583	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	75.16	75.16
26	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 2	1	DAY 2	2	24	DAY 1 DOSE	24	24	24	1D	24	2020-05-21	08:00	2			1	DRUG (ng/mL)	1	2	12.01	2.485983	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	12.01	12.01
27	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 2	1	DAY 2	2	24	DAY 1 DOSE	24	24	24	1D	24	2020-05-21	08:00	2			1	BIOMARKER (ng/mL)	2	5	89.63	4.495745	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	89.63	89.63
28	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 3	1	DAY 3	3	48	DAY 1 DOSE	48	48	48	2D	48	2020-05-21	08:00	3			1	DRUG (ng/mL)	1	2	10.18	2.320054	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	10.18	10.18
29	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 3	1	DAY 3	3	48	DAY 1 DOSE	48	48	48	2D	48	2020-05-21	08:00	3			1	BIOMARKER (ng/mL)	2	5	80.25	4.385157	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	80.25	80.25
30	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 4	1	DAY 4	4	72	DAY 1 DOSE	72	72	72	3D	72	2020-05-21	08:00	4			1	DRUG (ng/mL)	1	2	8.90	2.185528	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	8.90	8.9
31	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 4	1	DAY 4	4	72	DAY 1 DOSE	72	72	72	3D	72	2020-05-21	08:00	4			1	BIOMARKER (ng/mL)	2	5	78.60	4.364427	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	78.60	78.6
32	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 5	1	DAY 5	5	96	DAY 1 DOSE	96	96	96	4D	96	2020-05-21	08:00	5			1	DRUG (ng/mL)	1	2	8.31	2.117239	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	8.31	8.31
33	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 5	1	DAY 5	5	96	DAY 1 DOSE	96	96	96	4D	96	2020-05-21	08:00	5			1	BIOMARKER (ng/mL)	2	5	70.41	4.254365	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	70.41	70.41
34	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 6	1	DAY 6	6	120	DAY 1 DOSE	120	120	120	5D	120	2020-05-21	08:00	6			1	DRUG (ng/mL)	1	2	6.98	1.943693	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	6.98	6.98
35	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 6	1	DAY 6	6	120	DAY 1 DOSE	120	120	120	5D	120	2020-05-21	08:00	6			1	BIOMARKER (ng/mL)	2	5	75.25	4.320808	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	75.25	75.25
36	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 7	1	DAY 7	7	144	DAY 1 DOSE	144	144	144	6D	144	2020-05-21	08:00	7			1	DRUG (ng/mL)	1	2	2.25	0.810999	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	2.25	2.25
37	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 7	1	DAY 7	7	144	DAY 1 DOSE	144	144	144	6D	144	2020-05-21	08:00	7			1	BIOMARKER (ng/mL)	2	5	77.43	4.349329	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	77.43	77.43
38	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 8	1	DAY 8	8	168	DAY 1 DOSE	168	168	168	7D	168	2020-05-21	08:00	8			1	DRUG (ng/mL)	1	2	2.50	0.91774	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	2.50	2.5
39	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 8	1	DAY 8	8	168	DAY 1 DOSE	168	168	168	7D	168	2020-05-21	08:00	8			1	BIOMARKER (ng/mL)	2	5	85.56	4.449228	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	85.56	85.56
40	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 9	1	DAY 9	9	192	DAY 1 DOSE	192	192	192	8D	192	2020-05-21	08:00	9			1	DRUG (ng/mL)	1	2	2.94	1.078083	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	2.94	2.94
41	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 9	1	DAY 9	9	192	DAY 1 DOSE	192	192	192	8D	192	2020-05-21	08:00	9			1	BIOMARKER (ng/mL)	2	5	79.61	4.377099	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	79.61	79.61
42	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 10	1	DAY 10	10	216	DAY 1 DOSE	216	216	216	9D	216	2020-05-21	08:00	10			1	DRUG (ng/mL)	1	2	3.19	1.161523	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	3.19	3.19
43	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 10	1	DAY 10	10	216	DAY 1 DOSE	216	216	216	9D	216	2020-05-21	08:00	10			1	BIOMARKER (ng/mL)	2	5	61.60	4.120669	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	61.60	61.6
44	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 11	1	DAY 11	11	240	DAY 1 DOSE	240	240	240	10D	240	2020-05-21	08:00	11			1	DRUG (ng/mL)	1	2	1.04	0.043502	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	1.04	1.04
45	PROJECT-001	1	PROTOCOL-001	1	1	PROTOCOL-001-001-00137	100100137	00137	001	1	DAY 11	1	DAY 11	11	240	DAY 1 DOSE	240	240	240	10D	240	2020-05-21	08:00	11			1	BIOMARKER (ng/mL)	2	5	73.21	4.293272	0	0	2000	10	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg Single Dose	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	73.21	73.21
46	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	-0.1	DAY 1 MORNING DOSE	-0.1	0	0	PREDOSE	0	2020-01-21	07:54	1			1	DRUG (ng/mL)	1	2	.	.	0	1	10000	1	1	Y	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	.	BLQ
47	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	-0.1	DAY 1 MORNING DOSE	-0.1	0	0	PREDOSE	0	2020-01-21	07:54	1			1	BIOMARKER (ng/mL)	2	5	128.37	4.854907	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	128.37	128.37
48	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	0	DAY 1 MORNING DOSE	0	0	0	DOSE	0	2020-01-21	08:00	1			1	TEST PRODUCT (mg)	0	1		.	1	1						N	50	50	50	12	7	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30
49	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	0.25	DAY 1 MORNING DOSE	0.25	0.25	0.25	15MIN	0.25	2020-01-21	08:15	1			1	DRUG (ng/mL)	1	2	2.91	1.067237	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	2.91	2.91
50	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	0.25	DAY 1 MORNING DOSE	0.25	0.25	0.25	15MIN	0.25	2020-01-21	08:15	1			1	BIOMARKER (ng/mL)	2	5	103.27	4.637362	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	103.27	103.27
51	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	0.5	DAY 1 MORNING DOSE	0.5	0.5	0.5	30MIN	0.5	2020-01-21	08:30	1			1	DRUG (ng/mL)	1	2	4.39	1.478924	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	4.39	4.39
52	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	0.5	DAY 1 MORNING DOSE	0.5	0.5	0.5	30MIN	0.5	2020-01-21	08:30	1			1	BIOMARKER (ng/mL)	2	5	108.68	4.688433	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	108.68	108.68
53	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	0.75	DAY 1 MORNING DOSE	0.75	0.75	0.75	45MIN	0.75	2020-01-21	08:45	1			1	DRUG (ng/mL)	1	2	9.49	2.250409	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	9.49	9.49
54	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	0.75	DAY 1 MORNING DOSE	0.75	0.75	0.75	45MIN	0.75	2020-01-21	08:45	1			1	BIOMARKER (ng/mL)	2	5	113.54	4.732154	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	113.54	113.54
55	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	1	DAY 1 MORNING DOSE	1	1	1	1H	1	2020-01-21	09:00	1			1	DRUG (ng/mL)	1	2	14.46	2.671443	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	14.46	14.46
56	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	1	DAY 1 MORNING DOSE	1	1	1	1H	1	2020-01-21	09:00	1			1	BIOMARKER (ng/mL)	2	5	97.32	4.577994	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	97.32	97.32
57	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	1.5	DAY 1 MORNING DOSE	1.5	1.5	1.5	1H30MIN	1.5	2020-01-21	09:30	1			1	DRUG (ng/mL)	1	2	18.30	2.907014	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	18.30	18.3
58	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	1.5	DAY 1 MORNING DOSE	1.5	1.5	1.5	1H30MIN	1.5	2020-01-21	09:30	1			1	BIOMARKER (ng/mL)	2	5	105.71	4.660707	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	105.71	105.71
59	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	2	DAY 1 MORNING DOSE	2	2	2	2H	2	2020-01-21	10:00	1			1	DRUG (ng/mL)	1	2	13.58	2.608391	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	13.58	13.58
60	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	2	DAY 1 MORNING DOSE	2	2	2	2H	2	2020-01-21	10:00	1			1	BIOMARKER (ng/mL)	2	5	120.29	4.789945	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	120.29	120.29
61	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	3	DAY 1 MORNING DOSE	3	3	3	3H	3	2020-01-21	11:00	1			1	DRUG (ng/mL)	1	2	25.66	3.244865	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	25.66	25.66
62	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	3	DAY 1 MORNING DOSE	3	3	3	3H	3	2020-01-21	11:00	1			1	BIOMARKER (ng/mL)	2	5	105.01	4.654081	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	105.01	105.01
63	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	4	DAY 1 MORNING DOSE	4	4	4	4H	4	2020-01-21	12:00	1			1	DRUG (ng/mL)	1	2	21.00	3.044436	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	21.00	21
64	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	4	DAY 1 MORNING DOSE	4	4	4	4H	4	2020-01-21	12:00	1			1	BIOMARKER (ng/mL)	2	5	89.13	4.490147	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	89.13	89.13
65	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	6	DAY 1 MORNING DOSE	6	6	6	6H	6	2020-01-21	14:00	1			1	DRUG (ng/mL)	1	2	25.04	3.22044	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	25.04	25.04
66	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	6	DAY 1 MORNING DOSE	6	6	6	6H	6	2020-01-21	14:00	1			1	BIOMARKER (ng/mL)	2	5	124.90	4.827486	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	124.90	124.9
67	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	8	DAY 1 MORNING DOSE	8	8	8	8H	8	2020-01-21	16:00	1			1	DRUG (ng/mL)	1	2	19.16	2.95296	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	19.16	19.16
68	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	8	DAY 1 MORNING DOSE	8	8	8	8H	8	2020-01-21	16:00	1			1	BIOMARKER (ng/mL)	2	5	127.55	4.84854	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	127.55	127.55
69	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	12	DAY 1 MORNING DOSE	12	12	12	12H	12	2020-01-21	20:00	1			1	DRUG (ng/mL)	1	2	28.77	3.359384	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	28.77	28.77
70	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 1	1	DAY 1	1	12	DAY 1 MORNING DOSE	12	12	12	12H	12	2020-01-21	20:00	1			1	BIOMARKER (ng/mL)	2	5	110.85	4.708191	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	110.85	110.85
71	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 2	2	DAY 2	2	24	DAY 1 AFTERNOON DOSE	12	24	12	PREDOSE	0	2020-01-22	08:00	2			1	DRUG (ng/mL)	1	2	17.72	2.874591	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	17.72	17.72
72	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 2	2	DAY 2	2	24	DAY 1 AFTERNOON DOSE	12	24	12	PREDOSE	0	2020-01-22	08:00	2			1	BIOMARKER (ng/mL)	2	5	132.20	4.884353	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	132.20	132.2
73	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 3	3	DAY 3	3	48	DAY 2 AFTERNOON DOSE	12	48	12	PREDOSE	0	2020-01-23	08:00	3			1	DRUG (ng/mL)	1	2	17.01	2.833753	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	17.01	17.01
74	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 3	3	DAY 3	3	48	DAY 2 AFTERNOON DOSE	12	48	12	PREDOSE	0	2020-01-23	08:00	3			1	BIOMARKER (ng/mL)	2	5	118.36	4.773765	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	118.36	118.36
75	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 4	4	DAY 4	4	72	DAY 3 AFTERNOON DOSE	12	72	12	PREDOSE	0	2020-01-24	08:00	4			1	DRUG (ng/mL)	1	2	17.32	2.851861	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	17.32	17.32
76	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 4	4	DAY 4	4	72	DAY 3 AFTERNOON DOSE	12	72	12	PREDOSE	0	2020-01-24	08:00	4			1	BIOMARKER (ng/mL)	2	5	115.94	4.753035	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	115.94	115.94
77	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	95.9	DAY 4 AFTERNOON DOSE	11.06	96	12	PREDOSE	0	2020-01-25	07:54	5			2	DRUG (ng/mL)	1	2	17.32	2.851861	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	17.32	17.32
78	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	95.9	DAY 4 AFTERNOON DOSE	11.06	96	12	PREDOSE	0	2020-01-25	07:54	5			2	BIOMARKER (ng/mL)	2	5	128.37	4.854907	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	128.37	128.37
79	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	95.9	DAY 5 MORNING DOSE	0	95.9	0	DOSE	0	2020-01-25	0.333333	5			2	TEST PRODUCT (mg)	0	1		.	1	1							50	50	50	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30
80	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	96.25	DAY 5 MORNING DOSE	0.25	96.25	0.25	15MIN	0.25	2020-01-25	08:15	5			2	DRUG (ng/mL)	1	2	19.91	2.991088	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	19.91	19.91
81	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	96.25	DAY 5 MORNING DOSE	0.25	96.25	0.25	15MIN	0.25	2020-01-25	08:15	5			2	BIOMARKER (ng/mL)	2	5	103.27	4.637362	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	103.27	103.27
82	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	96.5	DAY 5 MORNING DOSE	0.5	96.5	0.5	30MIN	0.5	2020-01-25	08:30	5			2	DRUG (ng/mL)	1	2	21.39	3.06284	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	21.39	21.39
83	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	96.5	DAY 5 MORNING DOSE	0.5	96.5	0.5	30MIN	0.5	2020-01-25	08:30	5			2	BIOMARKER (ng/mL)	2	5	108.68	4.688433	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	108.68	108.68
84	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	96.75	DAY 5 MORNING DOSE	0.75	96.75	0.75	45MIN	0.75	2020-01-25	08:45	5			2	DRUG (ng/mL)	1	2	26.49	3.276828	0	1	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	26.49	26.49
85	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	96.75	DAY 5 MORNING DOSE	0.75	96.75	0.75	45MIN	0.75	2020-01-25	08:45	5			2	BIOMARKER (ng/mL)	2	5	113.54	4.732154	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	113.54	113.54
86	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	97	DAY 5 MORNING DOSE	1	97	1	1H	1	2020-01-25	09:00	5			2	DRUG (ng/mL)	1	2	31.46	3.448743	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	31.46	31.46
87	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	97	DAY 5 MORNING DOSE	1	97	1	1H	1	2020-01-25	09:00	5			2	BIOMARKER (ng/mL)	2	5	97.32	4.577994	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	97.32	97.32
88	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	97.5	DAY 5 MORNING DOSE	1.5	97.5	1.5	1H30MIN	1.5	2020-01-25	09:30	5			2	DRUG (ng/mL)	1	2	35.30	3.563942	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	35.30	35.3
89	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	97.5	DAY 5 MORNING DOSE	1.5	97.5	1.5	1H30MIN	1.5	2020-01-25	09:30	5			2	BIOMARKER (ng/mL)	2	5	105.71	4.660707	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	105.71	105.71
90	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	98	DAY 5 MORNING DOSE	2	98	2	2H	2	2020-01-25	10:00	5			2	DRUG (ng/mL)	1	2	30.58	3.420254	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	30.58	30.58
91	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	98	DAY 5 MORNING DOSE	2	98	2	2H	2	2020-01-25	10:00	5			2	BIOMARKER (ng/mL)	2	5	2120.29	4.789945	0	0	2000	10	1	Y	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	2120.29	2120.29
92	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	99	DAY 5 MORNING DOSE	3	99	3	3H	3	2020-01-25	11:00	5			2	DRUG (ng/mL)	1	2	42.66	3.753221	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	42.66	42.66
93	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	99	DAY 5 MORNING DOSE	3	99	3	3H	3	2020-01-25	11:00	5			2	BIOMARKER (ng/mL)	2	5	105.01	4.654081	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	105.01	105.01
94	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	100	DAY 5 MORNING DOSE	4	100	4	4H	4	2020-01-25	12:00	5			2	DRUG (ng/mL)	1	2	38.00	3.637538	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	38.00	38
95	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	100	DAY 5 MORNING DOSE	4	100	4	4H	4	2020-01-25	12:00	5			2	BIOMARKER (ng/mL)	2	5	89.13	4.490147	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	89.13	89.13
96	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	102	DAY 5 MORNING DOSE	6	102	6	6H	6	2020-01-25	14:00	5			2	DRUG (ng/mL)	1	2	42.04	3.738601	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	42.04	42.04
97	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	102	DAY 5 MORNING DOSE	6	102	6	6H	6	2020-01-25	14:00	5			2	BIOMARKER (ng/mL)	2	5	124.90	4.827486	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	124.90	124.9
98	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	104	DAY 5 MORNING DOSE	8	104	8	8H	8	2020-01-25	16:00	5			2	DRUG (ng/mL)	1	2	36.16	3.588025	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	36.16	36.16
99	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	104	DAY 5 MORNING DOSE	8	104	8	8H	8	2020-01-25	16:00	5			2	BIOMARKER (ng/mL)	2	5	127.55	4.84854	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	127.55	127.55
100	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	108	DAY 5 MORNING DOSE	12	108	12	12H	12	2020-01-25	20:00	5			2	DRUG (ng/mL)	1	2	45.77	3.823661	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	45.77	45.77
101	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 5	5	DAY 5	5	108	DAY 5 MORNING DOSE	12	108	12	12H	12	2020-01-25	20:00	5			2	BIOMARKER (ng/mL)	2	5	110.85	4.708191	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	110.85	110.85
102	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 6	6	DAY 6	6	120	DAY 5 MORNING DOSE	24	120	24	24H	24	2020-01-26	08:00	6			2	DRUG (ng/mL)	1	2	17.30	2.8508	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	17.30	17.3
103	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 6	6	DAY 6	6	120	DAY 5 MORNING DOSE	24	120	24	24H	24	2020-01-26	08:00	6			2	BIOMARKER (ng/mL)	2	5	110.99	4.709416	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	110.99	110.99
104	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 7	7	DAY 7	7	144	DAY 5 MORNING DOSE	48	144	48	2D	48	2020-01-27	08:00	7			2	DRUG (ng/mL)	1	2	3.32	1.199607	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	3.32	3.32
105	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 7	7	DAY 7	7	144	DAY 5 MORNING DOSE	48	144	48	2D	48	2020-01-27	08:00	7			2	BIOMARKER (ng/mL)	2	5	114.20	4.737937	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	114.20	114.2
106	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 8	8	DAY 8	8	168	DAY 5 MORNING DOSE	72	168	72	3D	72	2020-01-28	08:00	8			2	DRUG (ng/mL)	1	2	3.69	1.306348	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	3.69	3.69
107	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 8	8	DAY 8	8	168	DAY 5 MORNING DOSE	72	168	72	3D	72	2020-01-28	08:00	8			2	BIOMARKER (ng/mL)	2	5	126.20	4.837836	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	126.20	126.2
108	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 9	9	DAY 9	9	192	DAY 5 MORNING DOSE	96	192	96	4D	96	2020-01-29	08:00	9			2	DRUG (ng/mL)	1	2	4.33	1.466691	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	4.33	4.33
109	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 9	9	DAY 9	9	192	DAY 5 MORNING DOSE	96	192	96	4D	96	2020-01-29	08:00	9			2	BIOMARKER (ng/mL)	2	5	117.41	4.765707	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	117.41	117.41
110	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 10	10	DAY 10	10	216	DAY 5 MORNING DOSE	120	216	120	5D	120	2020-01-30	08:00	10			2	DRUG (ng/mL)	1	2	4.71	1.550131	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	4.71	4.71
111	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 10	10	DAY 10	10	216	DAY 5 MORNING DOSE	120	216	120	5D	120	2020-01-30	08:00	10			2	BIOMARKER (ng/mL)	2	5	90.86	4.509277	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	90.86	90.86
112	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 11	11	DAY 11	11	240	DAY 5 MORNING DOSE	144	240	144	6D	144	2020-01-31	08:00	11			2	DRUG (ng/mL)	1	2	0.00	0.43211	0	0	10000	1	1	Y	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	0.00	BLQ
113	PROJECT-001	1	PROTOCOL-002	2	1	PROTOCOL-002-001-00237	200100237	00237	001	1	DAY 11	11	DAY 11	11	240	DAY 5 MORNING DOSE	144	240	144	6D	144	2020-01-31	08:00	11			2	BIOMARKER (ng/mL)	2	5	107.97	4.68188	0	0	2000	10	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	DOSE ESCALATION	1	1	BEFORE CROSSOVER	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	TEST DRUG 100 mg BID	1	70	70	170	24.2	1.81	30	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	107.97	107.97
114	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	-0.1	CYCLE 1 DAY 1 DOSE	-0.1	0	0	PREDOSE	0	2020-09-21	07:54	1			1	DRUG (ng/mL)	1	2	.	.	0	1	10000	1	1	Y	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30		LLOQ <= 1
115	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	0	CYCLE 1 DAY 1 DOSE	0	0	0	DOSE	0	2020-09-21	08:00	1			1	TEST PRODUCT (mg)	0	1	.	.	1	1	10000	1	0	N	0	N	50	50	50	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30
116	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	0.25	CYCLE 1 DAY 1 DOSE	0.25	0.25	0.25	15MIN	0.25	2020-09-21	08:15	1			1	DRUG (ng/mL)	1	2	1.28	0.799881	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	1.28	1.28
117	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	0.5	CYCLE 1 DAY 1 DOSE	0.5	0.5	0.5	30MIN	0.5	2020-09-21	08:30	1			1	DRUG (ng/mL)	1	2	1.93	1.211567	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	1.93	1.93
118	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	0.75	CYCLE 1 DAY 1 DOSE	0.75	0.75	0.75	45MIN	0.75	2020-09-21	08:45	1			1	DRUG (ng/mL)	1	2	4.17	1.983053	0	1	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	4.17	4.17
119	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	1	CYCLE 1 DAY 1 DOSE	1	1	1	1H	1	2020-09-21	09:00	1			1	DRUG (ng/mL)	1	2	6.37	2.404086	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	6.37	6.37
120	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	1.5	CYCLE 1 DAY 1 DOSE	1.5	1.5	1.5	1H30MIN	1.5	2020-09-21	09:30	1			1	DRUG (ng/mL)	1	2	8.06	2.639658	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	8.06	8.06
121	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	2	CYCLE 1 DAY 1 DOSE	2	2	2	2H	2	2020-09-21	10:00	1			1	DRUG (ng/mL)	1	2	5.97	2.341034	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	5.97	5.97
122	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	3	CYCLE 1 DAY 1 DOSE	3	3	3	3H	3	2020-09-21	11:00	1			1	DRUG (ng/mL)	1	2	11.29	2.977508	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	11.29	11.29
123	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	4	CYCLE 1 DAY 1 DOSE	4	4	4	4H	4	2020-09-21	12:00	1			1	DRUG (ng/mL)	1	2	9.24	2.777079	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	9.24	9.24
124	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	6	CYCLE 1 DAY 1 DOSE	6	6	6	6H	6	2020-09-21	14:00	1			1	DRUG (ng/mL)	1	2	11.02	2.953083	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	11.02	11.02
125	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	8	CYCLE 1 DAY 1 DOSE	8	8	8	8H	8	2020-09-21	16:00	1			1	DRUG (ng/mL)	1	2	8.44	2.685603	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	8.44	8.44
126	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 1	1	12	CYCLE 1 DAY 1 DOSE	12	12	12	12H	12	2020-09-21	20:00	1			1	DRUG (ng/mL)	1	2	12.66	3.092027	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	12.66	12.66
127	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 1	1	CYCLE 1 DAY 2	2	23.917	CYCLE 1 DAY 1 DOSE	23.917	24	24	1D	24	2020-09-22	07:55	2			1	DRUG (ng/mL)	1	2	7.80	2.607234	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	7.80	7.8
128	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 2	1	CYCLE 1 DAY 2	1	0	CYCLE 1 DAY 2 DOSE	0	24	0	DOSE	0	2020-09-22	08:00	2			1	TEST PRODUCT (mg)	0	1		.	1	1	10000	1	0	N	0	N	50	50	50	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30
129	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 2	1	CYCLE 1 DAY 1	1	24.45	CYCLE 1 DAY 2 DOSE	0.45	24.5	0.5	30MIN	0.5	2020-09-22	08:27	2			1	DRUG (ng/mL)	1	2	2.28	0.824175	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	2.28	2.28
130	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 2	1	CYCLE 1 DAY 1	1	26	CYCLE 1 DAY 2 DOSE	2	26	2	2H	2	2020-09-22	10:00	2			1	DRUG (ng/mL)	1	2	7.05	1.953028	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	7.05	7.05
131	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 2	1	CYCLE 1 DAY 1	1	32	CYCLE 1 DAY 2 DOSE	8	32	8	8H	8	2020-09-22	16:00	2			1	DRUG (ng/mL)	1	2	9.95	2.297573	0	0	10000	1	0	N	0	N	50	50	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	9.95	9.95
132	PROJECT-001	1	PROTOCOL-005	3	1	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 1 DAY 3	1	CYCLE 1 DAY 3	1	48.17	CYCLE 1 DAY 3 DOSE	0	48	0	DOSE	0	2020-09-23	08:10	3			1	TEST PRODUCT (mg)	0	1	.	.	1	1	10000	1	0	N	0	N	50	50	50	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 50 mg	1	TEST DRUG 50 mg	1	CYCLE 1	1	1	CYCLE 1	TEST DRUG 50 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 50 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30
133	PROJECT-001	1	PROTOCOL-005	3	2	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 2 DAY 1	1	CYCLE 2 DAY 1	1	264	CYCLE 2 DAY 1 DOSE	0	264	0	DOSE	0	2020-10-02	08:00	12			1	TEST PRODUCT (mg)	0	1	.	.	1	1	10000	1	0	N	0	N	75	75	75	24	5	.	.	TABLET	1	ORAL	1	TEST DRUG 75 mg	1	TEST DRUG 75 mg	1	DOSE ESCALATION	1	1	CYCLE 2	TEST DRUG 75 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 75 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30
134	PROJECT-001	1	PROTOCOL-005	3	2	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 2 DAY 7	1	CYCLE 2 DAY 7	1	408	CYCLE 2 DAY 7 DOSE	0	408	0	DOSE	0	2020-10-08	08:00	18			1	TEST PRODUCT (mg)	0	1	.	.	1	1	10000	1	0	N	0	N	100	100	100	24	9	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg	1	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	CYCLE 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30
135	PROJECT-001	1	PROTOCOL-005	3	2	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 2 DAY 17	1	CYCLE 2 DAY 17	1	648	CYCLE 2 DAY 17 DOSE	0	648	0	DOSE	0	2020-10-18	08:00	28			1	TEST PRODUCT (mg)	0	1	.	.	1	1	10000	1	0	N	0	N	100	100	100	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg	1	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	CYCLE 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30
136	PROJECT-001	1	PROTOCOL-005	3	2	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 2 DAY 18	1	CYCLE 2 DAY 18	1	671.83	CYCLE 2 DAY 17 DOSE	-0.1	672	0	PREDOSE	0	2020-10-19	07:50	29			1	DRUG (ng/mL)	1	2	4.95	1.599388	0	1	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg	1	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	CYCLE 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	4.95	4.95
137	PROJECT-001	1	PROTOCOL-005	3	2	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 2 DAY 18	1	CYCLE 2 DAY 18	1	672	CYCLE 2 DAY 18 DOSE	0	672	0	DOSE	0	2020-10-19	08:00	29			1	TEST PRODUCT (mg)	0	1	.	.	1	1	10000	1	0	N	0	N	100	100	100	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg	1	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	CYCLE 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	.	.
138	PROJECT-001	1	PROTOCOL-005	3	2	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 2 DAY 18	1	CYCLE 2 DAY 18	1	672.5	CYCLE 2 DAY 18 DOSE	0.5	672.5	0.5	30MIN	0.5	2020-10-19	08:30	29			1	DRUG (ng/mL)	1	2	8.03	2.083185	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg	1	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	CYCLE 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	8.03	8.03
139	PROJECT-001	1	PROTOCOL-005	3	2	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 2 DAY 18	1	CYCLE 2 DAY 18	1	674	CYCLE 2 DAY 18 DOSE	2	674	2	2H	2	2020-10-19	10:00	29			1	DRUG (ng/mL)	1	2	24.83	3.212053	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg	1	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	CYCLE 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	24.83	24.83
140	PROJECT-001	1	PROTOCOL-005	3	2	PROTOCOL-005-003-00485	500300485	00485	003	3	CYCLE 2 DAY 18	1	CYCLE 2 DAY 18	1	680.33	CYCLE 2 DAY 18 DOSE	8	680	8	8H	8	2020-10-19	16:20	29			1	DRUG (ng/mL)	1	2	35.05	3.556776	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	TABLET	1	ORAL	1	TEST DRUG 100 mg	1	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	CYCLE 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	69	175	22.5	1.84	40	M	1	WHITE	1	Non-Hispanic	1	North America	1	UNITED STATES	1	1.2	1500	100	90	1	20	30	35.05	35.05
141	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	-0.1	DAY 1 DOSE	-0.1	0	0	PREDOSE	0	2021-01-07	07:54	1			1	DRUG (ng/mL)	1	2	.	.	0	1	10000	1	1	Y	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40		LLOQ <= 1
142	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	0	DAY 1 DOSE	0	0	0	DOSE	0	2021-01-07	08:00	1	2021-01-07	08:30	1	TEST PRODUCT (mg)	0	2	.	.	1	1	10000	1	0	N	0	N	100	100	100	0	0	200	0.5	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40
143	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	0.5	DAY 1 DOSE	0.5	0.5	0.5	30MIN	0.5	2021-01-07	08:30	1			1	DRUG (ng/mL)	1	2	14.76	2.691921	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	14.76	14.76
144	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	1.083	DAY 1 DOSE	1.083	1	1	1H	1	2021-01-07	09:03	1			1	DRUG (ng/mL)	1	2	13.28	2.586259	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	13.28	13.28
145	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	3	DAY 1 DOSE	3	3	3	3H	3	2021-01-07	11:00	1			1	DRUG (ng/mL)	1	2	12.53	2.528126	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	12.53	12.53
146	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	6	DAY 1 DOSE	6	6	6	6H	6	2021-01-07	14:00	1			1	DRUG (ng/mL)	1	2	13.69	2.616666	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	13.69	13.69
147	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	8.167	DAY 1 DOSE	8.167	8	8	8H	8	2021-01-07	16:06	1			1	DRUG (ng/mL)	1	2	12.32	2.511224	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	12.32	12.32
148	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	12	DAY 1 DOSE	12	12	12	12H	12	2021-01-07	20:00	1			1	DRUG (ng/mL)	1	2	8.62	2.154085	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	8.62	8.62
149	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	24.5	DAY 1 DOSE	24.5	24	24	24H	24	2021-01-08	08:30	2			1	DRUG (ng/mL)	1	2	6.34	1.846879	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	6.34	6.34
150	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	48	DAY 1 DOSE	48	48	48	48H	48	2021-01-09	08:00	3			1	DRUG (ng/mL)	1	2	2.32	0.841567	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	2.32	2.32
151	PROJECT-001	1	PROTOCOL-006	4	1	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY1	1	DAY1	1	72	DAY 1 DOSE	72	72	72	72H	72	2021-01-10	08:00	4			1	DRUG (ng/mL)	1	2	.	.	0	1	10000	1	1	Y	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	1	PERIOD 1	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	69	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40		LLOQ <= 1
152	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY14	2	DAY14	2	336	DAY 14 DOSE	0	336	0	DOSE	0	2021-01-21	08:00	14	2021-01-21	08:30	1	TEST PRODUCT (mg)	0	2	.	.	1	1	10000	1	0	N	0	N	100	100	100	0	0	200	0.5	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	72	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40
153	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY15	3	DAY15	3	360	DAY 15 DOSE	0	360	0	DOSE	0	2021-01-22	08:00	15	2021-01-22	08:30	1	TEST PRODUCT (mg)	0	2	.	.	1	1	10000	1	0	N	0	N	100	100	100	24	5	200	0.5	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	72	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40
154	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	503.9	DAY 20 DOSE	-0.1	504	0	PREDOSE	0	2021-01-28	07:54	21			1	DRUG (ng/mL)	1	2	9.66	2.267994	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	72	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	9.66	9.66
155	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	504	DAY 21 DOSE	0	504	0	DOSE	0	2021-01-28	08:00	21	2021-01-28	08:30	1	TEST PRODUCT (mg)	0	2	.	.	1	1	10000	1	0	N	0	N	100	100	100	0	0	200	0.5	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40
156	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	504.583	DAY 21 DOSE	0.583	504.5	0.5	30MIN	0.5	2021-01-28	08:36	21			1	DRUG (ng/mL)	1	2	24.288	3.189982	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	24.288	24.288
157	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	505	DAY 21 DOSE	1	505	1	1H	1	2021-01-28	09:00	21			1	DRUG (ng/mL)	1	2	22.676	3.121307	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	22.676	22.676
158	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	507	DAY 21 DOSE	3	507	3	3H	3	2021-01-28	11:00	21			1	DRUG (ng/mL)	1	2	21.398	3.063297	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	21.398	21.398
159	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	510.167	DAY 21 DOSE	6.167	510	6	6H	6	2021-01-28	14:06	21			1	DRUG (ng/mL)	1	2	21.765	3.080303	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	21.765	21.765
160	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	512	DAY 21 DOSE	8	512	8	8H	8	2021-01-28	16:00	21			1	DRUG (ng/mL)	1	2	19.867	2.98906	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	19.867	19.867
161	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	516.167	DAY 21 DOSE	12.167	516	12	12H	12	2021-01-28	20:06	21			1	DRUG (ng/mL)	1	2	28.895	3.363669	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	28.895	28.895
162	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	528	DAY 21 DOSE	24	528	24	24H	24	2021-01-29	08:00	22			1	DRUG (ng/mL)	1	2	15.11	2.715357	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	15.11	15.11
163	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	552	DAY 21 DOSE	48	552	48	48H	48	2021-01-30	08:00	23			1	DRUG (ng/mL)	1	2	6.34	1.846879	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	6.34	6.34
164	PROJECT-001	1	PROTOCOL-006	4	2	PROTOCOL-006-001-00013	600100013	00013	001	1	DAY21	4	DAY21	4	578	DAY 21 DOSE	74	576	72	72H	72	2021-01-31	10:00	24			1	DRUG (ng/mL)	1	2	2.32	0.841567	0	0	10000	1	0	N	0	N	100	100	0	0	0	.	.	IV	2	IV	2	TEST DRUG 100 mg	2	TEST DRUG 100 mg	1	DOSE ESCALATION	1	2	PERIOD 2	TEST DRUG 100 mg	1	TEST DRUG 100 mg Single Dose	1	TEST DRUG 100 mg	1	71	70	175	22.5	1.84	48	M	1	BLACK OR AFRICAN AMERICAN	2	Non-Hispanic	1	North America	1	UNITED STATES	1	1.07	1400	84	82	1.1	21	40	2.32	2.32

$warningHtml

Page tree

Example. popPK-Data-Standard-Example-combined example with and IV dose